Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours
Status:
Completed
Trial end date:
2019-01-08
Target enrollment:
Participant gender:
Summary
A Phase I, open-label, multicentre, dose-escalation study to investigate the safety,
pharmacokinetics and maximum tolerated dose (MTD) of AZD4785 in patients with advanced solid
tumours where KRAS may be an important driver of tumour survival.
Part A: Dose escalation in patients with solid tumours to evaluate safety, pharmacokinetics
and maximum tolerated dose (MTD). Once the maximum tolerated dose (MTD) is established, a
dose expansion cohort may be included in Part A, with up to an additional 6 patients to
further explore the PK, safety, tolerability, and preliminary anti-tumour activity of the
AZD4785 MTD for confirmation of the recommended phase 2 dose (RP2D).
Part B: Expansion cohort at the selected dose in patients with non-small cell lung cancer
(NSCLC) to evaluate PK parameters, safety, tolerability, and preliminary anti-tumour activity
of the AZD4785 RP2D as monotherapy in patients with NSCLC. Approximately 20 patients with
NSCLC (Two groups of approximately 10 patients each) with NSCLC will be enrolled to Part B.
Group 1 patients will have an option to provide tumour biopsies and Group 2 will be required
(mandatory) to provide paired tumour biopsies. Overall up to 12 patients in Group 2Part B
patients will be required (mandatory) to may provide paired tumour biopsies. A third group of
up to 20 patients with other tumour types and/or a potential different schedule may be added
based on the results seen in Parts A and B and any other emerging data and may also provide
biopsies.